- Home
- RYOJ vs KYNB Comparison
RYOJ vs KYNB Comparison
Compare RYOJ & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYOJ | KYNB |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | Japan | United States |
| Employees | N/A | 34 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 27.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RYOJ | KYNB |
|---|---|---|
| Price | $4.20 | $7.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 628.1K | 15.6K |
| Earning Date | 12-15-2025 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.04 | ★ $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.56 | $6.32 |
| 52 Week High | $11.43 | $9.58 |
Technical Indicators
Market Signals| Indicator | RYOJ | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 57.46 |
| Support Level | $1.97 | $7.49 |
| Resistance Level | $6.49 | $7.89 |
| Average True Range (ATR) | 0.67 | 0.35 |
| MACD | 0.18 | -0.00 |
| Stochastic Oscillator | 83.08 | 73.11 |
Price Performance
Historical ComparisonAbout RYOJ rYojbaba Co. Ltd.
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.